



**ANNOUNCEMENT**  
**SUMMARY OF MINUTES OF GENERAL MEETING OF SHAREHOLDERS**  
**OF FISCAL YEAR 2025**  
**PT KIMIA FARMA (PERSERO) Tbk**

The Board of Directors of PT Kimia Farma (Persero) Tbk (hereinafter referred to as the “**Company**”), having its domicile in Central Jakarta, hereby announces that the Board of Directors has convened the Company’s General Meeting of Shareholders of the Company for the Fiscal Year 2025 (hereinafter referred to as the “**Meeting**”) on:

Day/Date : Wednesday, June 3, 2026  
Time : 14.53 WIB until 17.56 WIB  
Venue : Access the KSEI Electronic General Meeting System (eASY.KSEI) via the link: <https://akses.ksei.co.id/> provided by KSEI

The Meeting was chaired by Mr. Stefan Looho, as the President Commissioner, concurrently serving as the Independent Commissioner of the Company, based on the resolution of the Board of Commissioners Number: KEP-003/KOM-KF/V/2026 dated May 22, 2026, regarding the Appointment of the Chairperson of the Extraordinary General Meeting of Shareholders of PT Kimia Farma (Persero) Tbk.

**A. Attendance of Board of Commissioners and Board of Directors**

The Meeting was physically attended by 5 (five) members of the Board of Commissioners and 6 (six) members of the Board of Directors as follows:

Board of Commissioners		Board of Directors	
President Commissioner, concurrently serving as Independent Commissioner	Mr. Stefan Looho	President Director	Mr. Djagad Prakasa Dwialam
Commissioner	Mrs. Sumarjati Arjoso	Director of Finance and Risk Management	Mr. Willy Meridian
Independent Commissioner	Mrs. Diah Kusumawardani	Director of Portfolio, Product, and Service	Mrs. Jasmine Kamiasti Karsono
Independent Commissioner	Mr. Fachmi Idris	Director of Production and Supply Chain	Mr. Hadi Kardoko
Commissioner	Mr. Suprianto	Director of Human Resources	Mr. Disril Revolin Putra
		Director of Commercial	Mr. Hanadi Setiarto

## B. Attendance Quorum of the Shareholders

Pursuant to Article 26 paragraph (1) of the Company's Articles of Association and Article 86 paragraph (1) of Law Number 40 of 2007 concerning Limited Liability Companies, as amended by Law Number 6 of 2023 concerning the Stipulation of Government Regulation in Lieu of Law Number 2 of 2022 concerning Job Creation into Law ("Company Law"), for **Agenda Items 1, 2, 3, 4, and 5**, the Meeting may be convened if attended by Shareholders representing more than  $\frac{1}{2}$  (one-half) of the total shares with valid voting rights.

Pursuant to Article 26 paragraph (2) of the Company's Articles of Association and Article 89 paragraph (5) of the Company Law, for **Agenda Item 6**, the Meeting may be convened if attended by the Series A Dwiwarna Shareholder and the other Shareholders and/or their lawful proxies representing at least  $\frac{3}{4}$  (three-fourths) of the total shares with valid voting rights.

Pursuant to Article 26 paragraph (4) of the Company's Articles of Association and Article 86 paragraph (1) of the Company Law, for **Agenda Item 7**, the Meeting may be convened if attended by the Series A Dwiwarna Shareholder and the other Shareholders and/or their lawful proxies representing more than  $\frac{1}{2}$  (one-half) of the total shares with valid voting rights.

Based on the Shareholders Register as of the Recording Date, namely Monday, 11 May 2026, and the Attendance List received from PT Datindo Entrycom as the Company's Share Registrar, we hereby report that the Shareholders present and/or represented at this Meeting, whether physically present (offline), electronically present (online), or granting proxy through the e-Proxy eASY.KSEI facility, consist of 1 (one) Series A Dwiwarna share and 5.000.237.899 (Five billion two hundred thirty-seven thousand eight hundred ninety-nine) Series B shares, or in total 5.000.237.900 (Five billion two hundred thirty-seven thousand nine hundred) shares, representing 89,8258753% of 5.566.589.677 (five billion five hundred sixty-six million five hundred eighty-nine thousand six hundred seventy-seven) shares, being the total number of shares with valid voting rights issued by the Company up to the date of the Meeting, consisting of:

- 1 (one) Series A Dwiwarna share; and
- 5.566.589.676 (five billion five hundred sixty-six million five hundred eighty-nine thousand six hundred seventy-six) Series B shares,

with a nominal value of Rp100 (one hundred Rupiah) per share, constituting the total number of shares issued by the Company up to this date.

## C. Meeting Agendas and Brief Explanation:

1. **Approval of the Company's Annual Report for Fiscal Year 2025 and Ratification of the Company's Consolidated Financial Statements for Fiscal Year 2025, the Board of Commissioners' Supervisory Duties Report for Fiscal Year 2025, as well as Ratification of the Report on the Implementation of the Micro and Small Business Funding Program (Program Pendanaan Usaha Mikro dan Usaha Kecil/PUMK), and the granting of full release and discharge (*volledig acquit et de charge*) to the Board of Directors for the management actions of the Company and to the Board of Commissioners for the supervisory actions of the Company carried out during Fiscal Year 2025.**

Brief Explanation:

1. Pursuant to Article 12 paragraph (2) letter b in conjunction with Article 19 and Article 22 paragraph (2) of the Company's Articles of Association, as well as Law Number 40 of 2007 concerning Limited Liability Companies, as amended (the "Company Law"), it is stipulated that:
  - a) the Board of Directors shall submit the Annual Report to the General Meeting of Shareholders ("GMS") after it has been reviewed by the Board of Commissioners;
  - b) the approval of the Annual Report, including the ratification of the financial statements and the report on the Supervisory Duties of the Board of Commissioners, shall be carried out by the GMS.
2. Article 33 paragraph (1) of the Regulation of the Minister of State-Owned Enterprises Number PER-1/MBU/03/2023 of 2023 concerning Special Assignments and the Social and Environmental Responsibility Program of State-Owned Enterprises ("**PerMen BUMN 01/2023**") stipulates that the financial statements and the report on the implementation of the SOE Social and Environmental Responsibility Program (TJSL BUMN) shall form an integral part of the quarterly reports and annual performance reports of SOEs, which shall be set out in a separate chapter.

**2. Determination of the Salary/Honorarium, including Facilities and Allowances for Fiscal Year 2026, as well as Performance-Based Remuneration for Fiscal Year 2025 for the Management of the Company.**

Brief Explanation:

Pursuant to the Company's Articles of Association, the Salary/Honorarium, Allowances and Facilities of the Board of Commissioners and the Board of Directors of the Company, as well as *tantiem*, must be resolved by the General Meeting of Shareholders ("GMS").

**3. Determination of the Public Accountant and/or Public Accounting Firm to Audit the Company's Consolidated Financial Statements and the Financial Statements of the PUMK Program for Fiscal Year 2026.**

Brief Explanation:

Pursuant to Article 22 of the Company's Articles of Association and Article 59 paragraph (1) of Financial Services Authority Regulation Number 15/POJK.04/2020 concerning the Planning and Conduct of General Meetings of Shareholders of Public Companies, the appointment and dismissal of a Public Accountant and/or Public Accounting Firm that will provide audit services on annual historical financial information must be resolved at the General Meeting of Shareholders ("GMS") of the Public Company by taking into consideration the proposal of the Board of Commissioners.

**4. Delegation of Authority to Approve the Company's Long-Term Plan (Rencana Jangka Panjang Perusahaan or "RJPP") for the 2026–2030 Period and the Company's Work Plan and Budget (Rencana Kerja dan Anggaran Perusahaan or "RKAP") for Fiscal Year 2027, including any amendments thereto, from the General Meeting of Shareholders ("GMS") to a party designated by the GMS.**

Brief Explanation:

Based on Article 17 paragraph (3) of the Company's Articles of Association concerning the Company's Long-Term Plan (RJPP) and Article 18 paragraph (2) concerning the Company's Work Plan and Budget (RKAP), it is stipulated that the RJPP and RKAP shall be approved by the GMS.

**5. Report on the Implementation of the Conversion of Mandatory Convertible Bonds (OWK) into shares to increase the Company's capital, as well as approval of the granting of authority to the Company's Board of Commissioners to state the amount of the increase in issued and paid-up capital.**

Brief Explanation:

Pursuant to Article 41 paragraphs (1) and (2) of Law Number 40 of 2007 concerning Limited Liability Companies, it is stipulated as follows:

- 1) Any increase in the Company's capital shall be carried out based on the approval of the GMS.
- 2) The GMS may delegate authority to the Board of Commissioners to approve the implementation of the GMS resolution as referred to in paragraph (1) for a period of no longer than 1 (one) year.

**6. Report on the Implementation of the Transfer/Disposal and Write-Off of the Company's Assets representing more than 50% of the Company's net assets, as approved in the Extraordinary General Meeting of Shareholders ("EGMS") of the Company dated 3 November 2025.**

Brief Explanation:

The Company has obtained approval from the Extraordinary General Meeting of Shareholders ("EGMS") held on 3 November 2025 to carry out the Transfer/Disposition and Write-Off of the Company's Assets representing more than 50% of the Company's net assets for the Company's purposes, which shall be conducted in the form of the sale of 38 (thirty-eight) Company assets consisting of land and buildings, namely:

- a. 1 (one) land asset located in Cikarang with a value of Rp347 billion to PT Bio Farma (Persero), being the Company's main shareholder with ownership of 89.82%, and therefore constituting an affiliated party.
- b. 37 (thirty-seven) other land and building assets to be disposed of through auction at the State Assets and Auction Service Office (Kantor Pelayanan Kekayaan Negara dan Lelang/KPKNL), which is planned to be conducted during the period from 2026 to 2029.

The Company needs to report that, as of the date hereof, the transaction for the transfer/disposal and write-off of the Company's assets has not yet been implemented and will be carried out in compliance with the prevailing laws and regulations, including Financial Services Authority Regulation No. 42/POJK.04/2020 concerning Affiliated Transactions and Conflict of Interest Transactions and Financial Services Authority Regulation No. 17/POJK.04/2020 concerning Material Transactions and Changes in Business Activities.

## **7. Changes in the Composition of the Company's Management**

### **Brief Explanation:**

Referring to the Company's Articles of Association, the Board of Commissioners and the Board of Directors shall be appointed and dismissed by the GMS.

## **D. Opportunity for Questions and/or Opinions during the Meeting**

1. Each Meeting Agenda is given the opportunity to ask questions.
2. Shareholders or their proxies have 3 (three) opportunities to submit questions and/or opinions at each discussion session on each Meeting Agenda.
3. Submission of questions and/or opinions submitted orally cannot be responded to.
4. The Chairperson of the Meeting may limit the time in the question-and-answer program for each Meeting Agenda.
5. The process of submitting questions and/or opinions for Shareholders who are physically present at the Meeting (offline) is as follows:
  - a. The Chairperson of the meeting will ask the shareholders if they have any questions or opinions to submit.
  - b. Questions and/or opinions that have been written by the Shareholders are submitted to the officer to be submitted to the Notary and Chairperson of the Meeting or the party appointed to provide an explanation.
6. The process of submitting questions and/or opinions for Shareholders electronically at the Meeting through eASY.KSEI, is as follows:
  - a. Questions and/or opinions are submitted through the chat feature in the 'Electronic Option' column available on the E-Meeting Hall screen at eASY.KSEI;
  - b. Questions and/or opinions can be submitted as long as the 'General Meeting Flow Text' column has the status of "discussion started for agenda item no. [...]".
7. Questions and/or opinions that have been submitted by the Shareholders or their proxies are then submitted to the Notary to examine their validity/authority.
8. Questions and/or opinions that have been examined by a Notary are submitted by officers to the Chairperson of the Meeting. The Chairperson of the Meeting will then read out the questions and/or opinions.
9. The Chairperson of the Meeting has the right to refuse to answer questions and/or opinions that are not related to the Meeting Agenda being discussed or that have been previously asked.
10. Members of the Board of Commissioners or members of the Board of Directors or parties appointed by the Chairperson of the Meeting will answer questions or respond to opinions that have been read out as referred to in point 9 above.
11. The Chairperson of the Meeting has the authority to take the necessary actions to maintain the orderliness of the Meeting.

## E. Meeting Resolution Mechanism

1. Meeting decisions are taken based on deliberation to reach a consensus. In the event that the Meeting decisions based on deliberation to reach a consensus is not reached, then the decision shall be taken by voting, with the following conditions:
  - a. Pursuant to Article 26 paragraph (1) of the Company's Articles of Association and Article 87 paragraph (2) of the Company Law, for **Agenda Items 1, 2, 3, 4, and 5**, a resolution shall be valid if approved by more than  $\frac{1}{2}$  (one-half) of the total shares with voting rights present at the Meeting.
  - b. Pursuant to Article 26 paragraph (2) of the Company's Articles of Association and Article 89 paragraph (5) of the Company Law, for **Agenda Item 6**, a resolution shall be valid if approved by the shareholders and/or their lawful proxies representing more than  $\frac{3}{4}$  (three-fourths) of the total shares with voting rights present at the Meeting.
  - c. Pursuant to Article 26 paragraph (4) of the Company's Articles of Association and Article 87 paragraph (2) of the Company Law, for **Agenda Item 7**, a resolution shall be valid if approved by the Series A Dwiwarna Shareholde and the other shareholders and/or their lawful proxies representing more than  $\frac{1}{2}$  (one-half) of the total shares with voting rights present at the Meeting.
2. Voting is conducted after all the questions have been answered and/or the question-and-answer time has expired.
3. Each share gives the holder the right to cast 1 (one) vote. If a Shareholder owns more than 1 (one) share, he/she is only required to give 1 (one) time and the vote represents all shares that he owns or represents.
4. The electronic (online) voting process for Shareholders in the Meeting through eASY.KSEI (*e-Voting*) is carried out in the following manner:
  - a. The voting process takes place on eASY.KSEI in the *E-Meeting Hall menu, Live Broadcasting* sub-menu;
  - b. Shareholders who are present or grant electronic proxy in the Meeting through eASY.KSEI, but have not yet cast their vote, have the opportunity to cast their vote during the voting period through the *E-Meeting Hall* screen on eASY.KSEI;
  - c. During the voting process, the '*General Meeting Flow Text*' column will display the status "*voting for agenda item no, [...] has started*";
  - d. If a Shareholder does not cast a vote for an Agenda Item until the status of the Meeting displayed in the '*General Meeting Flow Text*' column changes to "*voting for agenda item no [...] has ended*", then the Shareholder is considered to have abstained;
  - e. Direct electronic voting per Agenda Item via eASY.KSEI is allocated a maximum of 5 (five) minutes.
5. Shareholders of shares with valid voting rights who are present at the Meeting but abstain, in accordance with the provisions of Article 47 of POJK No.15/POJK.04/2020 and Article 25 paragraph (11) of the Articles of Association, shall be deemed to have cast votes in line with the majority of shareholders who cast votes.
6. The Chair of the Meeting shall request the Notary to announce the results of the voting.
7. The provisions referred to in this paragraph shall apply mutatis mutandis to Shareholders who grant proxy through e-Proxy.

## F. Independent Party for Vote Counting

The Company has appointed independent parties, PT Datindo Entrycom to count and/or validate the votes.

## G. Meeting Resolutions

Whereas the Meeting has resolved the following resolutions as set forth in “Minutes of the General Meeting of Shareholders of **PT PERUSAHAAN PERSEROAN (PERSERO) PT KIMIA FARMA Tbk**, abbreviated as **PT KIMIA FARMA (PERSERO) Tbk**”, Deed No. 02 dated 3 June 2026, made before Dewantari Handayani, S.H., MPA, Notary, the substance of which is as follows:

### First Meeting Agenda:

Approval of the Company’s Annual Report for Fiscal Year 2025 and Ratification of the Company’s Consolidated Financial Statements for Fiscal Year 2025, the Board of Commissioners’ Supervisory Duties Report for Fiscal Year 2025, as well as Ratification of the Report on the Implementation of the Micro and Small Business Funding Program (Program Pendanaan Usaha Mikro dan Usaha Kecil/PUMK), and the granting of full release and discharge (volledig acquit et de charge) to the Board of Directors for the management actions of the Company and to the Board of Commissioners for the supervisory actions of the Company carried out during Fiscal Year 2025.

### Number of Questioners

None of the Shareholders asked questions in the First Meeting Agenda.

### Voting Calculations

DISAGREE	ABSTAIN	AGREE (Including the Series A Dwiwarna Shareholder)
200.100 shares or 0,0040018%	0 share or 0,0000000%	5.000.037.800 shares or 99,9959982%

Pursuant to Article 47 of OJK Regulation Number 15/POJK.04/2020 and Article 26 paragraph (10) of the Company’s Articles of Association, Shareholders casting abstention votes shall be deemed to have cast the same vote as the majority vote of the Shareholders casting votes. Accordingly, the Meeting, by **majority vote** totaling **5.000.037.800** (five billion thirty-seven thousand eight hundred) shares, representing **99,9959982%** (ninety-nine point nine nine five nine nine eight two percent) of the total votes cast at the Meeting, resolved as follows:

1. To approve the Company’s Annual Report, including the Supervisory Duties Report of the Company’s Board of Commissioners for the Financial Year 2025 ended on 31 December 2025.
2. To Ratify:
  - a. The Company’s Consolidated Financial Statements for the Financial Year 2025 ended on 31 December 2025, which were audited by the Public Accounting Firm Heliantono & Rekan pursuant to Report Number 00425/2.0459/AU.1/04/0916-2/1/III/2026 dated 31 March 2026, expressing an unqualified opinion in all material respects; and

- b. The Financial Statements of the Micro and Small Business Financing Program (PUMK) for the 2025 Fiscal Year ending on December 31, 2025, which have been audited by the Public Accounting Firm Heliantono & Partners in accordance with Report No. 00760/2.0459/AU.8/04/0916-2/1/IV/2026 dated April 30, 2026, with an unqualified opinion in all material respects.
3. With the approval of the Company's Annual Report, including the Supervisory Duties Report of the Board of Commissioners, and the ratification of the Company's Consolidated Financial Statements as well as the Financial Statements of the PUMK Program, all for the Financial Year 2025 ended on 31 December 2025, the GMS hereby grants full release and discharge (volledig acquit et de charge) to all members of the Board of Directors for the management actions of the Company and to all members of the Board of Commissioners for the supervisory actions of the Company carried out during the Financial Year 2025 ended on 31 December 2025, insofar as such actions do not constitute criminal acts and/or violations of the prevailing laws and regulations and are reflected in the aforesaid reports.

**Second Meeting Agenda:**

Determination of the Salary/Honorarium, including Facilities and Allowances for Fiscal Year 2026, as well as Performance-Based Remuneration for Fiscal Year 2025 for the Management of the Company.

**Number of Questioners**

None of the Shareholders asked questions in the Second Meeting Agenda.

**Voting Calculations**

DISAGREE	ABSTAIN	AGREE (Including the Series A Dwiwarna Shareholder)
200.100 shares or 0,0040018%	0 share or 0,0000000%	5.000.037.800 shares or 99,9959982%

Pursuant to Article 47 of OJK Regulation Number 15/POJK.04/2020 and Article 26 paragraph (10) of the Company's Articles of Association, Shareholders casting abstention votes shall be deemed to have cast the same vote as the majority vote of the Shareholders casting votes. Accordingly, the Meeting, by **majority vote** totaling **5.000.037.800** (five billion thirty-seven thousand eight hundred) shares, representing **99,9959982%** (ninety-nine point nine nine five nine nine eight two percent) of the total votes cast at the Meeting, resolved as follows:

Approving the delegation of authority to:

1. The majority of Series B Shareholders to appoint members of the Board of Commissioners; and
2. The Board of Commissioners, after first obtaining written approval from the majority of Series B Shareholders, shall determine for members of the Board of Directors the following salaries/honoraria, benefits, and allowances for Fiscal Year 2026 and performance-based compensation for Fiscal Year 2025 in accordance with applicable regulations.

**Third Meeting Agenda:**

Determination of the Public Accountant and/or Public Accounting Firm to Audit the Company's Consolidated Financial Statements and the Financial Statements of the PUMK Program for Fiscal Year 2026.

**Number of Questioners**

None of the Shareholders asked questions in the Third Meeting Agenda.

**Voting Calculations**

<b>DISAGREE</b>	<b>ABSTAIN</b>	<b>AGREE (Including the Series A Dwiwarna Shareholder)</b>
200.100 shares or 0,0040018%	20.000 shares of 0,0004000%	5.000.017.800 shares or 99,9955982%

Pursuant to Article 47 of OJK Regulation Number 15/POJK.04/2020 and Article 26 paragraph (10) of the Company's Articles of Association, Shareholders casting abstention votes shall be deemed to have cast the same vote as the majority vote of the Shareholders casting votes. Accordingly, the Meeting, by **majority vote** totaling **5.000.037.800** (five billion thirty-seven thousand eight hundred) shares, representing **99,9959982%** (ninety-nine point nine nine five nine nine eight two percent) of the total votes cast at the Meeting, resolved as follows:

1. To grant authority and power to the Board of Commissioners of the Company, subject to obtaining prior approval from the majority Series B Shareholder, to determine the appointment of a Public Accountant and/or Public Accounting Firm to audit the Company's Consolidated Financial Statements for Fiscal Year 2026 and other periods within Fiscal Year 2026, and/or to audit certain specific financial statements in 2026, as well as the Financial Statements and the Implementation of the Micro and Small Enterprise (MSE) Funding Program for Fiscal Year 2026.
2. To grant authority and power to the Board of Commissioners, subject to obtaining prior approval from the majority Series B Shareholder, to determine the appointment of a Public Accountant and/or Public Accounting Firm to audit the Company's Consolidated Financial Statements for other periods within Fiscal Year 2026 for the purposes and interests of the Company.
3. To grant authority and power to the Board of Commissioners of the Company, subject to obtaining prior written approval from the majority Series B Shareholder, to determine the audit fees and other terms and conditions for such Public Accountant and/or Public Accounting Firm, and to appoint a replacement Public Accountant and/or Public Accounting Firm should the appointed Public Accountant and/or Public Accounting Firm, for any reason whatsoever, be unable to complete the audit of the Company's Consolidated Financial Statements and the Financial Statements and the Implementation of the Micro and Small Enterprise (MSE) Funding Program for Fiscal Year 2026, including determining the audit fees and other terms and conditions for such replacement Public Accountant and/or Public Accounting Firm.

#### **Fourth Meeting Agenda:**

Delegation of Authority to Approve the Company's Long-Term Plan (Rencana Jangka Panjang Perusahaan or "RJPP") for the 2026–2030 Period and the Company's Work Plan and Budget (Rencana Kerja dan Anggaran Perusahaan or "RKAP") for Fiscal Year 2027, including any amendments thereto, from the General Meeting of Shareholders ("GMS") to a party designated by the GMS.

#### **Number of Questioners**

None of the Shareholders asked questions in the Fourth Meeting Agenda.

#### **Voting Calculations**

<b>DISAGREE</b>	<b>ABSTAIN</b>	<b>AGREE (Including the Series A Dwiwarna Shareholder)</b>
220.100 shares or 0,0044018%	0 share or 0,0000000%	5.000.017.800 shares or 99,9955982%

Pursuant to Article 47 of OJK Regulation Number 15/POJK.04/2020 and Article 26 paragraph (10) of the Company's Articles of Association, Shareholders casting abstention votes shall be deemed to have cast the same vote as the majority vote of the Shareholders casting votes. Accordingly, the Meeting, by **majority vote** totaling **5.000.017.800** (five billion seventeen thousand eight hundred) shares, representing **99,9955982%** (ninety-nine point nine nine five five nine eight two percent) of the total votes cast at the Meeting, resolved as follows:

To approve the granting of authority and power to the Company's Board of Commissioners, upon obtaining prior written approval from the holder of the majority Series B Shares, to approve the Company's Long-Term Corporate Plan (RJPP) for 2026–2030 and the Company's Annual Work Plan and Budget (RKAP) for 2027, including any amendments thereto. The approval of the Company's RJPP for 2026–2030 and RKAP for 2027, including any amendments thereto, shall be carried out in accordance with good corporate governance principles and the prevailing regulations, with due regard to the principles of fairness and disclosure of information, and shall have been coordinated with the holder of the Series A Dwiwarna Share or its proxy for synchronization with Government policies.

#### **Fifth Meeting Agenda:**

Report on the Implementation of the Conversion of Mandatory Convertible Bonds (OWK) into shares to increase the Company's capital, as well as approval of the granting of authority to the Company's Board of Commissioners to state the amount of the increase in issued and paid-up capital.

#### **Number of Questioners**

None of the Shareholders asked questions in the Fifth Meeting Agenda.

### Voting Calculations

<b>DISAGREE</b>	<b>ABSTAIN</b>	<b>AGREE (Including the Series A Dwiwarna Shareholder)</b>
200.100 shares or 0,0040018%	20.000 shares of 0,0004000%	5.000.017.800 shares or 99,9955982%

Pursuant to Article 47 of OJK Regulation Number 15/POJK.04/2020 and Article 26 paragraph (10) of the Company's Articles of Association, Shareholders casting abstention votes shall be deemed to have cast the same vote as the majority vote of the Shareholders casting votes. Accordingly, the Meeting, by **majority vote** totaling **5.000.037.800** (five billion thirty-seven thousand eight hundred) shares, representing **99,9959982%** (ninety-nine point nine nine five nine nine eight two percent) of the total votes cast at the Meeting, resolved as follows:

1. Accept the Report on the Implementation of the Conversion of Mandatory Convertible Bonds (Obligasi Wajib Konversi/OWK) into the Company's shares in connection with the increase of the Company's capital.
2. Approve the granting of authority and power to the Board of Commissioners of the Company to declare the amount of the increase in the Company's issued and paid-up capital resulting from the conversion of the Company's Mandatory Convertible Bonds (OWK), as reflected in Article 4 paragraph (2) and Article 4 paragraph (3) of the Company's Articles of Association, and to take all necessary actions in connection therewith in compliance with the prevailing laws and regulations.
3. Grant an extension of authority and power to the Board of Commissioners of the Company, with the right of substitution, to set forth and declare all matters resolved under this agenda item in a notarial deed and to submit the same to the competent authorities in order to obtain approval and/or acknowledgment of receipt of notification of the amendment to the Articles of Association, and to take all actions deemed necessary and useful for such purposes without any exception whatsoever, including making any additions and/or amendments to such amendment to the Articles of Association if required.

### Sixth Meeting Agenda:

Report on the Implementation of the Transfer/Disposal and Write-Off of the Company's Assets representing more than 50% of the Company's net assets, as approved in the Extraordinary General Meeting of Shareholders ("EGMS") of the Company dated 3 November 2025.

### Number of Questioners

None of the Shareholders asked questions in the Sixth Meeting Agenda.

### Voting Calculations

<b>DISAGREE</b>	<b>ABSTAIN</b>	<b>AGREE (Including the Series A Dwiwarna Shareholder)</b>
220.100 shares or 0,0044018%	0 share or 0,0000000%	5.000.017.800 shares or 99,9955982%

Pursuant to Article 47 of OJK Regulation Number 15/POJK.04/2020 and Article 26 paragraph (10) of the Company's Articles of Association, Shareholders casting abstention votes shall be deemed to have cast the same vote as the majority vote of the Shareholders casting votes. Accordingly, the Meeting, by **majority vote** totaling **5.000.017.800** (five billion seventeen thousand eight hundred) shares, representing **99,9955982%** (ninety-nine point nine nine five five nine eight two percent) of the total votes cast at the Meeting, resolved as follows:

Accept the Report on the Implementation of the Transfer/Disposal and Write-off of the Company's Assets representing more than 50% (fifty percent) of the Company's net assets, as approved by the Company's Extraordinary General Meeting of Shareholders (EGMS) held on 3 November 2025.

**Seventh Meeting Agenda:**

Changes in the Composition of the Company's Management.

**Number of Questioners**

None of the Shareholders asked questions in the Seventh Meeting Agenda.

**Voting Calculations**

<b>DISAGREE</b>	<b>ABSTAIN</b>	<b>AGREE (Including the Series A Dwiwarna Shareholder)</b>
220.100 shares or 0,0044018%	0 share or 0,0000000%	5.000.017.800 shares or 99,9955982%

Pursuant to Article 47 of OJK Regulation Number 15/POJK.04/2020 and Article 26 paragraph (10) of the Company's Articles of Association, Shareholders casting abstention votes shall be deemed to have cast the same vote as the majority vote of the Shareholders casting votes. Accordingly, the Meeting, by **majority vote** totaling **5.000.017.800** (five billion seventeen thousand eight hundred) shares, representing **99,9955982%** (ninety-nine point nine nine five five nine eight two percent) of the total votes cast at the Meeting, resolved as follows:

Considering the provisions of Article 65 paragraph (1) of the Regulation of the Minister of State-Owned Enterprises (SOE) Number PER-3/MBU/03/2023 concerning the Organs and Human Resources of State-Owned Enterprises, the Articles of Association of PT Kimia Farma Tbk, the Special Power of Attorney Number SKK-42/MBU/10/2023 dated 13 October 2023, the Letter of the Head of the State-Owned Enterprises Governance Agency (BP BUMN) Number SR-277/BP/06/2026 dated 3 June 2026 regarding the Proposed Changes to the Management of PT Kimia Farma (Persero) Tbk (a subsidiary of PT Bio Farma (Persero)), and the Letter of Appointment from the President Director of PT Bio Farma (Persero) to the Director of Human Capital of PT Bio Farma (Persero) Number SD-012.02/DIR/VI/2026 dated 2 June 2026, as follows:

1. To approve the honorable dismissal of Mrs. Jasmine Kamiasti Karsono from her position as Director of Portfolio, Products & Services of PT Kimia Farma (Persero) Tbk.

2. To approve the change in the nomenclature of the position of a member of the Board of Directors of PT Kimia Farma (Persero) Tbk as follows:

<b>Current Position</b>	<b>New Position</b>
Director of Portfolio, Products & Services	-

3. To approve the appointment of Mr. Bonanza Perwira Taihitu as Commissioner of PT Kimia Farma (Persero) Tbk.
4. The dismissal, change in position nomenclature, and appointment of members of the Board of Directors and Board of Commissioners of PT Kimia Farma (Persero) Tbk as referred to in points 1, 2, and 3 above shall be resolved at the General Meeting of Shareholders (GMS) of PT Kimia Farma (Persero) Tbk, with due regard to the provisions of the Company's Articles of Association and the prevailing laws and regulations.
5. To grant authority to the Board of Directors of PT Kimia Farma (Persero) Tbk, with the right of substitution, to formalize the resolutions in an authentic deed before a notary or other authorized official, and to report the same to PT Bio Farma (Persero) as the Attorney-in-Fact of the Holder of Series A Dwiwarna Shares of PT Kimia Farma (Persero) Tbk.

**Jakarta, June 5, 2026**  
**PT Kimia Farma (Persero) Tbk**  
**Board of Directors**